PR – Enzymotec and AAK Establish a Joint Venture
Enzymotec is an Israeli biotech company, a developer and manufacturer of bio-functional ingredients for the dietary supplements, functional foods and infant formula markets.
29/06/07 Enzymotec and the 1.6 B$, specialty fat producer AarhusKarlshamn (AAK) Sweden have established a new Joint Venture: Advanced Lipids AB, for the production, sales and marketing of specialty functional ingredients to the food industry in particular for infant nutrition.
The two companies have already enjoyed a relationship dating back to 2003 for the production of Enzymotec's InFat, and have been operating the joint venture since last year. However the 50:50 JV was formally established this month.
The First product to be market under Advanced Lipids is InFat, which enables an optimal Calcium absorption and a reduced constipation for infants.
InFat is already used in Europe and South East Asia and gained GRAS status in the US.
"The cooperation with Enzymotec will further strengthen the AAK's market position in infant food business segment" says Hakan Christensson, President of AAK’s business area Food Ingredients Continental Europe.
“Enzymotec and AAK already work on the development of additional products to be marketed to the food industry. “ Says Mr. Yoav Kahane, Managing director at Advanced Lipids AB.
AAK is a world leader in specialty vegetable fats, having global position in three Business Areas; Chocolate and Confectionary Fats, Food Ingredients and Technical Products & Feed.
Enzymotec is an Israeli biotech company, a developer and manufacturer of bio-functional ingredients for the dietary supplements, functional foods and infant formula markets. Its key product categories are: SharpPS - phosphatidylserine for brain cognitive improvement, InFat and CardiaBeat - for reducing several CVD-risk factors simultaneously.
